Key result
Terlipressin significantly reduced norepinephrine doses from 480 to 110 ng/kg/min compared to standard therapy in patients with refractory vasoplegic syndrome.
Why the study?
Terlipressin is used abroad for refractory post-perfusion vasoplegic syndrome but is not registered in Russia for hypotension, warranting comparison with standard norepinephrine therapy.
Does terlipressin reduce the need for norepinephrine in patients with refractory postperfusion vasoplegic syndrome after on-pump cardiac surgery?
RCT (n=34)
Randomized
No
Does terlipressin reduce the need for norepinephrine in patients with refractory postperfusion vasoplegic syndrome after on-pump cardiac surgery?
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Krichevsky et al. (2021) conducted an RCT in Severe refractory postperfusion vasoplegic syndrome (n=34). Terlipressin vs. Norepinephrine (standard therapy) was evaluated on Reduction in norepinephrine doses. Terlipressin significantly reduced norepinephrine doses from 480 to 110 ng/kg/min compared to standard therapy in patients with refractory vasoplegic syndrome.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: